J. Willey, An Marx, B. Lim, N. Ibrahim, V. Valero, E. Mittendorf, J. Reuben, H. Le-Petross, G. Whitman, S. Krishnamurthy, W. Woodward, A. Lucci, Diane D. Liu, Yu Shen, N. Ueno
{"title":"摘要:一项使用talimogene laherparepvec作为单药治疗炎性乳腺癌或不能手术局部复发的非炎性乳腺癌患者的II期研究","authors":"J. Willey, An Marx, B. Lim, N. Ibrahim, V. Valero, E. Mittendorf, J. Reuben, H. Le-Petross, G. Whitman, S. Krishnamurthy, W. Woodward, A. Lucci, Diane D. Liu, Yu Shen, N. Ueno","doi":"10.1158/1538-7445.SABCS17-OT1-01-05","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19476,"journal":{"name":"Ongoing Clinical Trials","volume":"38 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Abstract OT1-01-05: A phase II study using talimogene laherparepvec as a single agent for inflammatory breast cancer or non-inflammatory breast cancer patients with inoperable local recurrence\",\"authors\":\"J. Willey, An Marx, B. Lim, N. Ibrahim, V. Valero, E. Mittendorf, J. Reuben, H. Le-Petross, G. Whitman, S. Krishnamurthy, W. Woodward, A. Lucci, Diane D. Liu, Yu Shen, N. Ueno\",\"doi\":\"10.1158/1538-7445.SABCS17-OT1-01-05\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19476,\"journal\":{\"name\":\"Ongoing Clinical Trials\",\"volume\":\"38 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-02-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ongoing Clinical Trials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1538-7445.SABCS17-OT1-01-05\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ongoing Clinical Trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7445.SABCS17-OT1-01-05","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Abstract OT1-01-05: A phase II study using talimogene laherparepvec as a single agent for inflammatory breast cancer or non-inflammatory breast cancer patients with inoperable local recurrence